Search
Cabergoline
go.drugbank.com/drugs/DB00248ApprovedInvestigationalIt is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor AgonistsProducts: CABASER 4 MG TABLET, 16 ADET, CABASER 1 MG TABLET, 20 ADETBrexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigationalIt also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. … Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor AgonistsProducts: REXULTI (BREXPIPRAZOLE) TABLETS 1 MG, REXULTI (BREXPIPRAZOLE) TABLETS 2 MGOsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalApproximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. … Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersSynonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamideSelinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigational[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. … [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: Nexpovio 20 mg Film Kaplı Tablet, 16 TABLET, Nexpovio 20 mg Film Kaplı Tablet, 20 TABLETEnfuvirtide
go.drugbank.com/drugs/DB00109ApprovedInvestigationalEnfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake … The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesProducts: FUZEON POLVO SOLUCION INYECTABLE 90 MG/MIUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. … It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: RINVOQ 30 mg extended-release film coated tablets, Rinvoq 30 mg Uzatılmış Salımlı Tablet, 28 ADETFrovatriptan
go.drugbank.com/drugs/DB00998ApprovedFrovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. … Frovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor AgonistsProducts: NEWART 2.5 MG TABLET, 12 ADET, MIGREX 2.5 MG FILM TABLET, 12 ADETIxazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US. … [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: 2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diacetic acidDalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalDalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072 … Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073].
Products: Dalbavancin Accord 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Dalbavancin ratiopharm 500 mg Pulver für ein Konzentrat zur Herstellung einer InfusionslösungPerflutren
go.drugbank.com/drugs/DB00556ApprovedInvestigationalWhen exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. … Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane
Products: CIPROFLOXACINO TABLETAS X 500 MG